TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Inscripta Stock

Inscripta Stock

inscripta.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $459.69MM

Inscripta, founded in 2015, a biomanufacturing company that specializes in genome engineering, and the developer of a gene-editing technology. The proprietary gene-editing technology offers trackable editing of single cells at scale, aiming to “bring affordable and sustainable synthetic biology to market”.

Buy or sell Inscripta stockLearn more about Inscripta IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Inscripta, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Inscripta’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Inscripta.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Inscripta investors also invested in these private companies

Venrock
D1 Capital Partners
Durable Capital Partners
Paladin Capital Group
Foresite Capital

Team

Management Team

Ron Mcgrath
Chief Financial Officer
Andrew Garst Ph.D
Co-Founder & Chief Innovation Officer
Sri Kosaraju
Chief Executive Officer, President & Board Member
Ted Tarasow Ph.D
Chief Technology Officer

Board Members

Bryan Roberts Ph.D
Venrock
Roger Wyse Ph.D
Spruce Capital Partners
Eric Moessinger
NanoDimension

Frequently Asked Questions About Inscripta’s Stock

plusminus
Can you buy Inscripta stock?
Inscripta is not publicly traded on NYSE or NASDAQ in the U.S. To buy Inscripta stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Inscripta stock?
Yes, you can sell stock of a private company like Inscripta. Forge can help you sell your Inscripta stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Inscripta’s stock price?
Inscripta is a privately held company and therefore does not have a public stock price. However, you may access Inscripta’s private market stock price with Forge Data.
plusminus
What is Inscripta’s stock ticker symbol?
Inscripta does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Inscripta in the BioTech & Pharma sector

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

Atomwise

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$405.17MM

Mammoth Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.08B

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Ginkgo Bioworks

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.89B

Caris Life Sciences

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

Business Wire 01/10/2022
Ginkgo Bioworks Adopts Inscripta’s Onyx Digital Genome Engineering Platform to Continue Accelerating its Genome Editing Throughput
Inscripta, the digital genome engineering company, today announced that Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, has adopted the Onyx™ genome engineering platform in its foundries.
EU Startups 05/31/2021
Finnish startup Inscripta raises €700K to grow its speech recognition technology | EU-Startups
The Finnish language technology company Inscripta Oy has raised a total of 700K in funding for the further development of its self-developed speech recognition technology and final solutions. Having begun operations in 2016, Inscripta is a 16-person software company that has developed a comprehensive and versatile end-to-end speech recognition solution for healthcare organizations and other […]
FINSMES 04/05/2021
Inscripta Closes $150M Series E Financing | FinSMEs
Inscripta, Inc., a Boulder, CO-based digital genome engineering company, closed a $150m Series E financing

Trending Companies

Frequently Asked Questions

Updated on: Dec 1, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.